Skip to content
Parnax Lab logo

Parnax Lab

PARNAXLAB NSE
₹103.00 down 0.25 (0.24%)
Market Cap
₹118 Cr
P/E
13.22

Parnax Lab (PARNAXLAB) share price was ₹103.25 at the 28 Oct 2026 close; market capitalisation ₹119 Cr; P/E (TTM) 13.25; sector Healthcare. The share price fell 19.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 6.4% year on year to ₹56.80 Cr and net profit fell 86.9% year on year to ₹0.43 Cr (compared with Jun 2025). Promoters held 72.30% of Parnax Lab in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 52/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹103.25 −30.40 −22.75% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹118 Cr
P/E (TTM)
13.22
EBITDA
₹31.00 Cr
Return on Equity
12.38%
Debt to Equity
0.87
Book Value
₹82.83
EPS (TTM)
₹7.79
52W High
₹182.00
52W Low
₹90.00

Price-based figures as of 29 Oct 2026, 09:38 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,607.8072.341,75,266 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,186.70108.041,18,150 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.9034.681,11,755 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.1032.701,10,281 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Parnax Lab (this company)
₹103.0013.22118 Cr1.240.00%12.38%16.40%256 Cr9 Cr
Median 8 companies₹1,566.3034.871,18,018 Cr4.710.47%13.09%17.17%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

52 Average
Overall score

Data confidence 100/100

Category scores

Quality Good 59
Returns, margins, earnings quality 22% weight
Valuation Good 60
Cheap vs sector & own history 24% weight
Growth Strong 80
Sales & profit trajectory 9% weight
Financial Health Poor 26
Solvency, leverage, coverage 9% weight
Momentum Poor 14
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
12
Neutral
5
Bullish
2

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
33.21% higher than 3Y

change over 1 year

Net Income Growth
2.61% lower than 3Y

change over 1 year

Cash Flow Change
-75.23%

change over 1 year

EBITDA Margin Change
-18.11%

change over 1 year Operating margin 7.59% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
48.74
42.61
50.99
46.37
50.12
48.36
40.22
49.04
53.38
62.6
62.94
69.63
56.8
Expenses
42.24
37.32
45.02
40.58
41.5
41.12
35.95
42.41
45.94
54.52
56.09
64.75
52.49
Operating Profit
6.5
5.29
5.97
5.79
8.62
7.24
4.27
6.63
7.44
8.08
6.85
4.88
4.31
OPM %
13.34%
12.41%
11.71%
12.49%
17.2%
14.97%
10.62%
13.52%
13.94%
12.91%
10.88%
7.01%
7.59%
Other Income
0.24
0.22
0.1
0.25
0.11
0.95
0.19
0.43
0.18
0.63
-0.17
1.76
0.15
Interest
1.16
1.43
1.35
1.41
1.5
1.38
1.23
1.28
1.22
1.4
1.47
1.61
1.64
Depreciation
1.6
1.74
1.78
1.84
1.83
1.94
1.79
1.83
1.94
2.1
1.96
2.04
2.22
PBT
3.98
2.34
2.94
2.79
5.4
4.87
1.44
3.95
4.46
5.21
3.25
2.99
0.6
Tax %
16.33%
20.09%
25.85%
19.35%
26.3%
29.77%
16.67%
26.08%
26.46%
30.33%
16.62%
27.09%
28.33%
Net Profit
3.33
1.87
2.18
2.24
3.99
3.42
1.21
2.93
3.28
3.62
2.71
2.19
0.43
EPS (₹)
2.89
1.63
1.9
1.95
3.47
2.97
1.05
2.54
2.85
3.16
2.36
1.9
0.37
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
103
71
95
106
109
95
90
163
168
189
188
249
252
Expenses
91
61
82
95
99
89
80
140
145
165
161
221
228
Operating Profit
12
10
13
10
10
6
10
23
23
24
27
27
24
OPM %
12%
14%
14%
10%
9%
7%
11%
14%
14%
12%
14%
11%
10%
Other Income
1
1
0
1
2
1
0
0
1
1
1
2
2
Interest
4
4
5
4
4
5
5
5
5
5
5
6
6
Depreciation
3
3
4
4
4
4
5
6
7
7
7
8
8
PBT
5
3
5
3
5
-2
0
12
12
12
16
16
12
Tax %
22%
28%
22%
65%
28%
48%
350%
33%
30%
20%
26%
26%
—
Net Profit
4
3
4
1
3
-3
0
8
9
10
12
12
9
EPS (₹)
5.01
2.95
4.33
1.23
3.88
-3.42
-0.42
8.4
7.51
8.37
10.03
10.26
7.79
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
10
11
11
11
11
Reserves
17
19
23
24
27
24
24
38
51
60
72
84
Borrowings
41
42
39
37
42
51
59
69
55
81
70
83
Other Liabilities
17
10
15
18
17
23
15
36
28
38
37
50
Total Liabilities
83
79
86
87
95
107
106
153
145
190
190
228
Fixed Assets
36
38
47
44
51
58
60
72
77
89
88
115
CWIP
1
2
0
0
0
3
5
3
2
21
29
11
Investments
1
1
0
0
0
0
0
0
0
0
0
0
Other Assets
45
38
38
43
43
46
41
78
66
80
72
101
Total Assets
83
79
86
87
95
107
106
153
145
190
190
228
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
3
16
13
9
9
6
9
21
16
32
8
Investing
-4
-6
-10
-5
-11
-13
-7
-16
-10
-32
-16
-16
Financing
6
1
-5
-7
1
5
0
12
-14
15
-16
8
Net Cash Flow
1
-2
0
1
-1
0
0
4
-3
-1
0
0
Free Cash Flow
-4
-3
5
8
-3
-4
0
-8
11
-16
16
-9
CFO/EBITDA
15
46
134
134
99
153
71
38
103
79
130
42
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
100
72
65
64
88
68
85
61
63
60
56
Inventory Days
38
64
50
45
52
76
80
73
79
94
87
82
Days Payable
51
30
48
45
44
74
46
81
53
74
72
73
Cash Conversion Cycle
71
134
74
64
72
90
102
77
86
83
75
65
Working Capital Days
16
7
-26
-8
0
-31
-66
-35
-19
-23
-24
-11
ROCE %
16%
11%
14%
11%
12%
3%
6%
17%
15%
13%
14%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Parnax Lab insights

61 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

Promot.72.30%Others4.99%Public22.71%As ofSep 2026
9.41% of promoter holding pledged as of 14 Oct 2026

Documents

Frequently Asked Questions about Parnax Lab

What does Parnax Lab Ltd do?
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]
Where is Parnax Lab Ltd (PARNAXLAB) listed?
Parnax Lab Ltd trades as PARNAXLAB on the NSE and under code 506128 on the BSE.
Which sector does Parnax Lab Ltd belong to?
Parnax Lab Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Parnax Lab Ltd?
Parnax Lab Ltd has a market capitalisation of ₹118.3 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Parnax Lab Ltd?
Parnax Lab Ltd trades at a PE ratio of 13.22 as of 29 Oct 2026, on earnings per share of ₹7.79, against a book value of ₹82.83 per share.
What is the 52-week high and low of Parnax Lab Ltd?
Over the last 52 weeks Parnax Lab Ltd has traded between ₹90 and ₹182 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Parnax Lab Ltd?
Parnax Lab Ltd reported a return on equity of 12.38%. Its debt-to-equity ratio is 0.87.

Company Information

Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]

Website naxparlab.com
Listed 2026-08-17
Face Value ₹ 10
Shares Outstanding 1,14,85,616

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506128.md for Parnax Lab Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month